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ABSTRACT: We have incorporated daunomycin, an antineoplastic agent, into a biode-
gradable hydrogel through a labile covalent bond. In brief, sodium alginate was chemi-
cally broken down to low molecular weight and followed by oxidation to prepare poly-
(aldehyde guluronate). Adipic dihydrazide was used to incorporate the drug into the
polymer backbone and cross-link the polymer to form hydrogels. Daunomycin can be
released from the hydrogel after the hydrolysis of the covalent linkage between the drug
and the polymer. A wide range of release profiles of daunomycin (e.g., from 2 days to 6
weeks) has been achieved using these materials, and the biological activity of the
released daunomycin was maintained. © 2000 Wiley-Liss, Inc. and the American Pharma-
ceutical Association J Pharm Sci 89: 910–919, 2000
Keywords: hydrogel; poly(aldehyde guluronate); daunomycin; covalent cross-linking;
controlled delivery
INTRODUCTION
One common approach in the treatment of cancer
is the delivery of antineoplastic agents to the tu-
mor. However, to achieve complete eradication of
tumors, antineoplastic agents must be adminis-
tered in high doses intravenously, which unfortu-
nately leads to the killing of healthy cells in ad-
dition to the cancer cells. Adverse side effects can
include severe immunosuppression, myelosup-
pression, nephrotoxicity, and cardiotoxicity.1,2 In
theory, the localized delivery of potent agents at
the required concentration should eradicate can-
cer cells without causing any damage to healthy
tissues and organs. This method may then allow
one to deliver antineoplastic agents in a con-
trolled manner over a wide range of time frames
depending on the type, size, and growth rate of
the tumor. There have been many attempts to
deliver antineoplastic agents using various deliv-
ery systems to circumvent adverse side effects
and to enhance the efficiency of the drugs.3–12
Hydrogels have been widely investigated as de-
livery vehicles for the localized, sustained release
of bioactive agents.13,14 Many synthetic and natu-
rally derived materials have been reported to
form hydrogels,15–18 and one widely used hydro-
gel is formed from the ionic cross-linking of so-
dium alginate, a linear polysaccharide isolated
from seaweed. Alginate is comprised of (1,4)-
linked b-D-mannuronic and a-L-guluronic acid
residues arranged in blocks of polymannuronate,
polyguluronate, and alternating units of both sug-
ars. Divalent cations, such as calcium, ionically
cross-link the carboxylate groups on adjacent al-
ginate strands to form hydrogels. The polyguluro-
nate block of alginate is known to be responsible
for this gelling feature.19 The favorable properties
of alginate, including nonimmunogenicity, hydro-
philicity, and relatively low cost have prompted
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attempts to use this material as wound dressing,
dental impression, and immobilization scaffolds
for cultured and transplanted cells.20–22 Alginate
is considered to be a biocompatible polymer,23 al-
though contaminating factors may induce signifi-
cant inflammation if the polymer is not suitably
purified.24 Alginate hydrogels have been previ-
ously proposed for a number of drug delivery ap-
plications.25–27 One disadvantage of alginate hy-
drogels is that they are not chemically broken
down in mammals. They instead dissolve in an
uncontrollable and unpredictable manner follow-
ing the dissolution of calcium into the surround-
ing medium. Furthermore, the molecular weight
of intact alginate is typically above the renal
clearance threshold, thus preventing it from be-
ing excreted from the body.28
To overcome these disadvantages, we have re-
cently synthesized new hydrogels composed of low
molecular weight polymers derived from algi-
nate.29 In brief, alginate was hydrolyzed under
acidic conditions and the polyguluronic acid
blocks were isolated, transformed to sodium
polyguluronate, and oxidized to yield poly(alde-
hyde guluronate) (PAG). PAG was then cross-
linked with adipic dihydrazide to form biodegrad-
able hydrogels with enhanced and easily con-
trolled mechanical properties. We now report the
utilization of these hydrogels to deliver an anti-
neoplastic agent, daunomycin, in a controlled
manner over a wide range of time frames. Dau-
nomycin was covalently attached to PAG via a
dihydrazide spacer, resulting in the formation of
hydrazone bonds between the polymer and the
daunomycin. The drug was released from the hy-
drogel by the hydrolysis of the hydrazone bond.
The release of daunomycin from the hydrogel was
monitored in vitro and was controlled by varying
the amount of covalent or ionic cross-linking of
the hydrogels. The bioavailability of the released
drug was tested in vitro as well.
EXPERIMENTAL SECTION
Materials
Sodium alginate was purchased from Pronova
Biomaterials (Drammen, Norway). Sodium perio-
date, adipic dihydrazide, ethylene glycol, and cal-
cium chloride were purchased from Aldrich
Chemical Company (Milwaukee, WI) and were
used as received. Daunomycin hydrochloride was
purchased from Fluka Chemical Corporation
(Ronkonkoma, NY). Dulbecco’s Modified Eagle’s
Medium (DMEM) was purchased from Life Tech-
nologies (Grand Island, NY). KB cells (an estab-
lished line of human epidermoid carcinoma cells)
were a gift from Dr. John Drach (Department of
Biologic & Materials Sciences, University of
Michigan).
Instruments
The ultraviolet/visible (UV/vis) spectra were col-
lected on a Perkin Elmer Lambda 12 UV/VIS
spectrophotometer. High-performance liquid
chromatography (HPLC) analysis was performed
with a Hewlett Packard Series II 1090 liquid
chromatograph with a photodiode array detector
and a Phenomenex Hypersil C18 column. The sys-
tem was programmed for gradient elution start-
ing with 82/18 ([0.025% aqueous acetic acid]/
CH3CN, v/v) for 2 min then raised to 50/50 during
4 min then back to 82/18. The elution of the drug
was monitored at 480 nm wavelength.
Synthesis of Daunomycin–Adipoyl
Hydrazide Hydrochloride
A 500-mL round-bottomed flask was wrapped
with aluminum foil and charged with daunomy-
cin hydrochloride (25 mg, 44.3 mmol) and adipic
dihydrazide (434 mg, 2.49 mmol). Methanol (250
mL) was added, and the reaction was stirred at
room temperature in the dark for 5 days. The sol-
vent was concentrated to 50 mL under reduced
pressure. The precipitated adipic dihydrazide was
removed by filtration, and the filtrates were con-
centrated to 5 mL under reduced pressure. Chlo-
roform (5 mL) was added in a dropwise manner
while shaking, and the mixture was cooled at 4 °C
overnight. More adipic dihydrazide precipitated.
The solvent was carefully transferred into a 25-
mL scintillation vial with a Pasteur pipette, leav-
ing the precipitate behind. The solvent was evap-
orated under reduced pressure to yield 25.2 mg of
product (35 mmol, 80% yield) that was analyzed
by thin-layer chromatography (TLC) on Kodak
13181 silica gel in CHCl3/CH3OH (80/20) (dauno-
mycin hydrochloride: Rf 4 0.39; daunomycin–
adipoyl hydrazide: Rf 4 0.1).
Synthesis of the Poly(aldehyde guluronate) (PAG)
PAG was synthesized according to a previously
reported procedure.29 Briefly, sodium alginate
was hydrolyzed under acidic conditions and the
polyguluronic acid oligomers were isolated at pH
2.85. Polyguluronic acid was then dissolved in wa-
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ter with the addition of aqueous sodium hydrox-
ide. Sodium polyguluronate was then precipitated
with ethanol, filtered, and dried under reduced
pressure; MW 6200 Da; Mw/Mn 1.14; FTIR (KBr
pellet, cm−1) 3430.5, 2931.2, 1616.4, 1412.5,
1320.5, 1126, 1092, 1028; 1H NMR (360 MHz,
D2O, d): 3.90 (br, s), 3.99 (br, s), 4.07 (br, s), 4.45
(br, s), 5.03 (br, s); 13C NMR (360 MHz, D2O, d):
67.64, 69.87, 71.73, 82.94, 103.66, 178.29. An
aqueous solution of sodium polyguluronate was
then oxidized with sodium periodate in the dark
at ambient temperature. The product was puri-
fied by extensive dialysis (Molecular Weight Cut
Off (MWCO 1000)) against double-distilled water
for 3 days. The solution was concentrated, frozen,
and lyophilized to yield PAG; MW 6000 Da, Mw/
Mn 1.4; FTIR (KBr pellet, cm
−1) 3336.5, 2942,
1724, 1616.4, 1405.8, 1321.1, 1159.4, 1117.2,
1025.8. The aldehyde content was quantified us-
ing trinitrobenzene sulfonic acid.29
Preparation of Covalent Cross-Linked
PAG Hydrogels
Daunomycin hydrochloride (10 mL, 25 mg/mL so-
lution in DMSO) was added to aqueous solutions
of adipic dihydrazide (25–125 mL, 0.5 M) in 5-mL
sterile tubes. After 10 min, aqueous solutions of
PAG (150–200 mL, 20% w/w) were added and the
total volume was diluted to 500 mL with Dulbec-
co’s Modified Eagle’s Medium (DMEM, pH 7.4)
containing penicillin and streptomycin (100 units/
mL and 100 mg/mL, respectively). The solutions
were mixed thoroughly for 30 s and allowed to
stand at room temperature for 1 h to form hydro-
gels. In the Results section of this manuscript,
hydrogels are described by their final PAG con-
centrations (% w/w) and final adipic dihydrazide
concentrations (mM).
Preparation of Ionic and Covalent Cross-Linked
PAG Hydrogels
Daunomycin hydrochloride (10 mL, 25 mg/mL so-
lution in DMSO) was added to aqueous solutions
of adipic dihydrazide (25–125 mL, 0.5 M) in 5-mL
sterile tubes. After 10 min, aqueous calcium chlo-
ride (20 mL, 1 M) was added followed by aqueous
solutions of PAG (150–200 mL, 20% w/w). The to-
tal volume was adjusted to 500 mL with DMEM
and the gels were formed as already described.
Determination of the Swelling Ratio of
the Hydrogels
Hydrogels were formed at various concentrations
of PAG, adipic dihydrazide, and calcium chloride
in 24-well plates. The hydrogels were immersed
in DMEM (pH 7.4) and incubated at 37 °C for 24
h to reach the equilibrium swelling. The hydro-
gels were transferred to 2-mL vials and weighed
(wet weight). The gels were then frozen and ly-
ophilized, and the dried samples were weighed
(dry weight). The swelling ratio was defined as
the ratio (wet weight − dry weight)/(dry weight).
We have corrected for the contribution of amino
acids and salts in DMEM by subtracting this
value from the weights of the wet and dry gels.
Determination of the Incorporated Daunomycin
To quantify the amount of daunomycin that is
incorporated in the gels, two sets of hydrogels
were formed as already described. One set was
loaded with daunomycin hydrochloride (0.20 mg,
0.355 mmol) and the other with trypan blue (0.32
mg, 0.333 mmol). After gelation, the hydrogels
were frozen and lyophilized. The dried solid in
each tube was crushed and 2 mL of double-
distilled water was added. The solutions were
then sonicated for 30 min, quantitatively trans-
ferred to 5-mL volumetric flasks, and diluted with
double-distilled water. Each solution was filtered
through a 0.22-mm filter, and the concentration of
the dissolved drug was quantified spectrophoto-
metrically at 480 nm for daunomycin and 588 nm
for trypan blue.
In Vitro Release of Daunomycin in Fresh Medium
Hydrogels were formed in 15-mL sterile tubes
as already described. Aqueous solutions of 5 mL
of DMEM containing penicillin and streptomy-
cin were added to each gel. The hydrogels were
then incubated at 37°C, and the medium was
replaced with fresh DMEM (5 mL) periodically.
The concentration of the released drug in the me-
dium was quantified spectrophotometrically at
480 nm.
In Vitro Release of Daunomycin in Spent Medium
Spent media was obtained from cultured KB cells.
Approximately 2 × 104 cells were seeded in a 162-
cm2 flasks containing 50 mL of media and incu-
bated at 37 °C for 3 to 4 days until cells had ap-
proximately reached confluency. The pH of the
collected media was not significantly different
from fresh media (pH 7.4). Hydrogels containing
daunomycin (10 mL, 25 mg/mL in DMSO) were
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formed at 6% w/w PAG and 150 mM adipic dihy-
drazide. The hydrogels were exposed to 2.5 mL of
spent Minimal Essential Media with Hanks’ salts
(MEMH) without phenol red that contained 10%
calf serum and penicillin/streptomycin (100 units/
mL and 100 mg/mL, respectively). The medium
was replaced weekly, and the concentration of
daunomycin that was released from the hydrogels
in spent media was determined at 480 nm.
Cytotoxicity Assay with KB Cells
The inhibitory concentrations of the released dau-
nomycin that killed 50% of the cells (IC50) were
determined using an established cytotoxicity as-
say with KB cells as described previously.30 Hy-
drogels at a final concentration of 6% w/w PAG
and 150 mM adipic dihydrazide containing 250 mg
of daunomycin were prepared and incubated in 5
mL of sterile media at 37 °C. The media was
tested and replaced with fresh media (5 mL) pe-
riodically. As a control, a set of hydrogels were not
loaded with the drug and treated in the same
fashion as just described. The KB cells were cul-
tured and seeded at a density of 5 ± 103 cells/well
in 96-well plates with a total volume of tissue cul-
ture medium of 200 mL/well. Cells were allowed to
attach for 1 day before adding drug solutions or
aliquots from the collected samples. Eight dilu-
tions were used for each sample (each being one-
third the concentration of the previous dilution).
After 48 h, cells were fixed with 95% ethanol for 5
min, rinsed with tap water, and stained with 2.5
mM crystal violet in 20% aqueous methanol for 5
min. The plates were rinsed again with tap water
and 150 mL/well acidified ethanol (0.01 M HCl)
was added to elute the dye from stained cells. The
concentration of the dye in each well was mea-
sured spectrophotometrically at 570 nm. Dose–
response curves were generated by plotting per-
cent inhibition ([sample absorbance/control ab-
sorbance] × 100) versus the log of the daunomycin
concentration and fit to a line. The IC50 values
were calculated using the equations for the best
linear fit. The IC50 values of daunomycin released
from the hydrogels exposed to both fresh and
spent media were compared with those of dauno-
mycin stored in DMSO or daunomycin conjugated
with adipic dihydrazide for 15 min before adding
to the cells. Solutions containing only PAG, adipic
dihydrazide, or material released from the hydro-




Commercially available high molecular weight al-
ginate was hydrolyzed under acidic conditions to
breakdown the b-glycosidic linkages between the
mannuronate and guluronate residues as previ-
ously described.29 Polyguluronic acid was then
precipitated at pH 2.85, filtered, and reconsti-
tuted in water by adjusting the pH to 7 with so-
dium hydroxide to yield sodium polyguluronate.
Sodium polyguluronate was then oxidized with
sodium periodate to yield the PAG. The degree of
oxidation was controlled by the mole equivalent of
sodium periodate used in each reaction. The de-
gree of oxidation of PAG used in this study was 87
± 1%.29 The molecular weight and polydispersity
of PAG did not significantly differ from the start-
ing sodium polyguluronate. The average number
of aldehyde groups per chain was estimated to be
67 groups. PAG was subsequently cross-linked
with a bifunctional cross-linker, adipic dihydra-
zide, to form hydrogels (Figure 1). A high effi-
ciency of this coupling was previously confirmed
using Fourier transform-infrared (FT-IR) spectra
and quantification of the cross-link density.29,31
The degree of swelling of PAG hydrogels was ana-
lyzed after the hydrogels had reached the equili-
brium swelling in aqueous DMEM. The swelling
ratio ranged from 15.5 to10.5 for hydrogels made
with varying extents of cross-linking (Table 1). As
expected, increasing the cross-link density re-
sulted in a decrease in the water content in these
hydrogels. The swelling was minimally affected
by alterations in the concentration of the polymer
used in this study. This finding may be attributed
to the low molecular weight of the PAG chains
utilized to form these hydrogels.
Daunomycin Incorporation
Drugs from the anthracyclin family had been pre-
viously incorporated into polymeric carriers for
systemic drug delivery via the formation of hydra-
zone bonds.32,33 The ketone group on the C13 po-
sition of these drugs reacts with pendant hydra-
zide groups on the polymer backbone. A similar
reaction was utilized in this paper to incorporate
daunomycin into hydrogels for localized drug de-
livery. Aqueous solutions of daunomycin and
adipic dihydrazide were mixed for 10 min before
the addition of aqueous PAG solutions. During
this time, daunomycin reacts with adipic dihydra-
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zide to form the daunomycin–adipoyl hydrazide
conjugate. In theory, one hydrazide terminal of
adipic dihydrazide reacts with the drug to form a
hydrazone bond, whereas the other terminal is
free because a large excess amount of adipic di-
hydrazide was used (Figure 2). The free hydrazide
group of the daunomycin–adipoyl hydrazide con-
jugate potentially reacts with an aldehyde group
on the backbone of PAG to form a labile hydra-
zone bond. The rest of the adipic dihydrazides po-
tentially cross-link PAG to form hydrogels.
Daunomycin hydrochloride and adipic dihydra-
zide were mixed in water to form daunomycin–
adipoyl hydrazide. The reaction was monitored
with TLC. After 15 min incubation at room tem-
perature, unreacted free daunomycin could be de-
tected at all concentrations of adipic dihydrazide
(50–250 mM). The reaction was complete after 6 h
of incubation at room temperature. HPLC was
then used to quantitate the amount of daunomy-
cin that reacted with adipic dihydrazide before
the addition of PAG. Daunomycin hydrochloride
and adipic dihydrazide were mixed at room tem-
perature and analyzed 15 min later. The mixture
Figure 2. Scheme for the coupling of daunomycin to
poly(aldehyde guluronate) hydrogels: (a) aqueous
adipic dihydrazide; and (b) aqueous PAG.
Figure 1. Synthesis of cross-linked poly(aldehyde gu-
luronate) hydrogels: (a) reflux in aqueous hydrochloric
acid followed by neutralization; (b) aqueous sodium
periodate; and (c) aqueous adipic dihydrazide.







6.0 100 40 15.4 ± 0.4
6.0 150 40 11.3 ± 0.1
6.0 200 40 11.0 ± 0.1
6.0 250 40 10.6 ± 0.2
6.0 150 0 14.2 ± 0.2
7.0 150 0 13.3 ± 0.2
8.0 150 0 12.8 ± 0.3
a Hydrogels were prepared under various conditions; hy-
drogels were immersed in DMEM (pH 7.4) and incubated at
37°C for 24 h.
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contained 88.5% ± 0.5 of the daunomycin–adipoyl
hydrazide conjugate and 11.5% ± 0.4 of free drug
(Figure 3). The amount of daunomycin that was
covalently incorporated into the hydrogel was
next determined by quantifying the amount of
free drug in the hydrogel. Hydrogels containing
daunomycin hydrochloride or trypan blue were
synthesized, frozen, lyophilized, and crushed to
form powders. The free drug was then dissolved
in water and the resulting mixture was filtered to
remove any fine particles. The concentration of
the free drug was then determined spectrophoto-
metrically. Trypan blue was used as a control be-
cause it does not contain aldehyde or ketone
groups for coupling to PAG and has a comparable
molecular weight to daunomycin. Only 2% of the
trypan blue was retained in the hydrogel. In com-
parison, 86.9 ± 0.1% of daunomycin remained in
the gelatinous particles. Similar results were ob-
tained when ethanol was used to extract dauno-
mycin and trypan blue. Moreover, hydrogels con-
taining trypan blue that were incubated in
DMEM released the entire drug within 24 h (data
not shown). To eliminate the possibility that ionic
interactions between the carboxylate groups on
the polymer backbone and the ammonium group
on the sugar ring of daunomycin control drug re-
lease, the release of daunomycin and daunomyci-
n–adipoyl hydrazide conjugate from sodium algi-
nate hydrogels was investigated. Alginate hydro-
gels cross-linked with calcium released the total
loaded drug and conjugate within 24 h in DMEM
(data not shown). The alginate hydrogels used in
this study exhibited the swelling ratios of 33.5 ±
1.9 and 46.9 ± 1.2 before and after drug release,
respectively. These findings clearly indicate that
daunomycin is covalently coupled to the PAG hy-
drogel through the adipic dihydrazide molecule.
The daunomycin incorporation in the hydrogels
correlates well with the percentage of daunomy-
cin–adipic dihydrazide conjugate that was deter-
mined by HPLC analysis.
In Vitro Release
The release of the free drug from the hydrogel
may be controlled by the chemical hydrolysis of
the hydrazone bond between the drug and the
adipic dihydrazide spacer, followed by the diffu-
sion of the drug from the hydrogel.34 However,
the hydrolysis of the linkage between adipic dihy-
drazide and PAG could also release the daunomy-
cin–adipoyl hydrazide conjugate. In this case, an
inactive form of the drug would be released (pro-
drug), which would be later activated by the hy-
drolysis of the linkage between adipic dihydrazide
and daunomycin. To determine the percentage of
free drug that is released, samples were periodi-
cally analyzed by HPLC. Uncoupled free dauno-
mycin was quantitatively released from cross-
linked PAG hydrogels at all times (Figure 3c).
These results suggest that hydrolysis of the hy-
Figure 3. Reversed-phase (Hypersil C18) liquid chro-
matographic analysis of (a) daunomycin, (b) daunomy-
cin–adipoyl hydrazide, and (c) daunomycin released
from PAG hydrogels. The mobile phase consisted of
H2O/CH3CN (82/18, v/v) and the aqueous component
contained 0.025% v/v acetic acid.
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drazone linkage between drug and adipic dihy-
drazide is the dominant reaction in drug release.
In the next series of experiments hydrogels
were formed with daunomycin while varying the
concentrations of adipic dihydrazide, calcium
ions, and PAG. The release profile of the incorpo-
rated daunomycin from the hydrogel changed sig-
nificantly depending on the concentration of
adipic dihydrazide, calcium ions in the hydrogel,
and PAG. In the first experiment, 6% w/w PAG
hydrogels at various concentration of adipic dihy-
drazide were prepared. Hydrogels cross-linked at
50 mM of adipic dihydrazide released the loaded
drug completely in 2 days (Figure 4). As the con-
centration of the cross-linker was increased, the
release rate of daunomycin was decreased. All in-
corporated drug was released in 2 weeks at 100
mM adipic dihydrazide, and in >6 weeks at el-
evated concentrations of adipic dihydrazide. It is
important to note that at low concentrations of
adipic dihydrazide, the complete release of dau-
nomycin was accompanied by the complete disso-
lution of the hydrogel. Hydrogels with low cross-
link density degrade at a faster rate (unpublished
results).
Ionic cross-linking of PAG with calcium ions
contributes to the physical properties of cross-
linked PAG hydrogels in a similar manner as ob-
served with alginate.29 The calcium ions cross-
link the carboxylate groups on adjacent PAG
strands. To investigate the effect of calcium cross-
linking on the release profile of daunomycin,
aqueous solutions of 6% w/w PAG containing 250
mg daunomycin hydrochloride were cross-linked
at 150 mM adipic dihydrazide. In the absence of
calcium ions in the hydrogels, a linear release of
1% of the incorporated drug per day was observed
during the first 10 days followed by ∼4% release
per day for the following 22 days (Figure 5). The
total incorporated drug was released in 32 days.
It is important to note that calcium ions are pres-
ent in the medium at physiological concentrations
in these studies. In the presence of 40 mM CaCl2
in the hydrogel, only 40% of the incorporated drug
was released during the first 6 weeks, and it was
released at a rate of 0.8% per day. The calcium
cross-linking results in hydrogels with a high
cross-linking density and a decreased pore size,
which likely decreased the release of the drug
from the hydrogel.
The extracellular pH of most tumors is slightly
lower than that of normal tissues35,36 which could
affect the release kinetics of drugs from PAG hy-
drogels. To investigate the possible role of pH on
drug release, the release of daunomycin from 6%
w/w PAG hydrogels at 150 mM adipic dihydrazide
was monitored at different pH conditions (Figure
Figure 4. The cumulative release of daunomycin over
time from hydrogels cross-linked by 50 mM (❋), 100
mM (j), 150 mM (d), 200 mM (m), and 250 mM (s) of
adipic dihydrazide. All hydrogels were formed with 6%
w/w PAG and 20 mM CaCl2, and release was monitored
following incubation in DMEM (pH 7.4) at 37 °C.
Figure 5. The cumulative release of daunomycin over
time from 6% w/w PAG hydrogels cross-linked by 150
mM adipic dihydrazide in the absence of calcium chlo-
ride (d) and in the presence of 40 mM calcium chloride
(l). Release was monitored following incubation in
DMEM (pH 7.4) at 37 °C.
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6). Daunomycin was released at a rate of 1% per
day from hydrogels incubated at neutral condi-
tion, but daunomycin was released at a signifi-
cantly higher rate (1.8% per day) from hydrogels
incubated in acidic medium (pH 6). This result is
likely caused by the higher rate of hydrolysis of
hydrazone bonds under acidic conditions.37,38 The
minimal further change in the release as the pH
was further lowered to pH 5 could be related to
several factors. The change in hydrolysis from pH
6 to 5 may not be significant. Alternatively, the
hydrogel is polyanionic and as the pH decreases, a
higher percentage of the carboxyl groups are pro-
tonated. This situation may cause changes in the
gel structure that alter the drug diffusion (e.g.,
changing pore size in gel).
Antitumor Activity of Released Daunomycin
The antitumor activity of the daunomycin re-
leased from PAG hydrogels was evaluated in vitro
using a standard cytotoxicity assay with KB
cells.29 The media collected from control hydro-
gels had no effect on cell growth. The IC50 of the
daunomycin–adipoyl hydrazide conjugate (in the
presence of 100-fold excess of adipic dihydrazide)
was 0.224 ± 0.091 mM compared with 0.202 ±
0.048 mM for the free daunomycin (Table 2). The
activity of the released daunomycin slightly de-
creased during the first 3 weeks, suggesting that
the released drug might be partially degraded.
The glycosidic linkage between the daunosamine
and daunomycinone units of the drug has been
previously reported to undergo hydrolytic cleav-
age under neutral to basic conditions.39,40 The ac-
tivity of daunomycin released in spent media did
not differ significantly from that released in fresh
media (data not shown). PAG and adipic dihydra-
zide were also tested to ensure that the noted cy-
totoxicity was not caused by these components of
the hydrogels. Neither aqueous PAG nor adipic
dihydrazide had a significant effect on the growth
of KB cells over the range of concentrations tested
(Table 2).
CONCLUSIONS
We have developed a novel biodegradable hydro-
gel for the sustained local delivery of daunomycin
over time frames ranging from a few days to sev-
eral weeks. We propose that cross-linked poly(al-
dehyde guluronate) hydrogels loaded with dauno-
mycin or other antineoplastic agents (containing
aldehyde or ketone groups) can deliver these
agents in vivo in a sustained manner. This system
may provide a potent vehicle for the localized de-
livery of antineoplastic agents in a minimally in-
vasive manner.
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Figure 6. The cumulative release of daunomycin over
time at pH 5 (d), pH 6 (s), and pH 7.4 (j). All hydro-
gels were formed with 6% w/w PAG and 150 mM adipic
dihydrazide and release was monitored following incu-
bation in DMEM at 37 °C.
Table 2. Inhibitory Activity of Intact or Released
Daunomycin Towards KB Cells over Time
Sample IC50 (mM)
Free daunomycin 0.202 ± 0.048
Daunomycin–adipic dihydrazide 0.224 ± 0.091
Released daunomycin after 1 week 0.560 ± 0.149
Released daunomycin after 2 weeks 0.349 ± 0.176
Released daunomycin after 3 weeks 0.805 ± 0.229
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